The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care

This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors.

Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of frontline treatment in achieving long-term disease control. You will also hear from David Lewis, MBChB, PhD, FRCPath, Plymouth University, Plymouth, UK, Tycel Phillips, MD, City of Hope, Duarte, CA, and Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, who share perspectives on patient selection for therapy, biological risk factors, and how treatment decisions differ between academic and community settings.